Loading…
Access to Life-Saving Medicine Act
Legislative Progress
Introduced
February 15, 2007
Latest Action
February 27, 2007
Primary Sponsor
Charles E. SchumerDemocratic(NY)
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
78pct
12d open
vs 3,722 other S bills in the 110th — cohort avg 42d
No CRS summary is available for this bill yet. The source title, actions, sponsors, and text versions below come from Congress.gov.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Bills with similar content found using semantic analysis.
Sources: Congress.gov
H.R.3200 America's Affordable Health Choices Act of 2009 S.1796 America's Healthy Future Act of 2009 H.R.3962 Affordable Health Care for America Act H.R.3590 Patient Protection and Affordable Care Act H.R.4872 Health Care and Education Reconciliation Act of 2010 S 75 - Generics First Act 2009 S 301 - Physician Payments Sunshine Act of 2009 H.R.759 Food and Drug Administration Globalization Act of 2009 HR 276 - Proper Disposal of Unused Pharmaceuticals S1213 Patient-Centered Outcomes Research Act of 2009 HR 4702, HR 4990 - A bill to amend title XIX of the Social Security Act to include all public clinics for the distribution of pediatric vaccines under the Medicaid program. HR 4705 HR 4993, S 2466 - Vaccines for the uninsured Adult Act of 2008 HR 1259 Dextromethorphan Distribution Act of 2009 S 1383 Dextromethorphan Abuse Reduction Act of 2009 S 256 Combat Methamphetamine Enhancement Act of 2009 HR 2923 Combat Methamphetamine Enhancement Act of 2009 HR 1038, S623 - Access to Life-Saving Medicine Act HR 1548 Pathway for Biosimilars Act HR 1427 - Promoting Innovation and Access to Life-Saving Medicine Act S 726 - Promoting Innovation and Access to Life-Saving Medicine Act S.1232 - Pharmaceutical Market Access and Drug Safety Act of 2009 HR 1548 - To amend the Public Health Service Act to establish a pathway for the licensure of biosimilar biological products, and for other purposes S 525 - Pharmaceutical Market Access and Drug Safety Act of 2009 21st Century Cancer Bill Personalized Medicine Public Health Service Act Drug Importation Gene Therapy PDUFA
Client expense: $1,000,000 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, U.S. Agency for International Development (USAID), U.S. Trade Representative (USTR)
H.R.3200 America's Affordable Health Choices Act of 2009 S.1796 America's Healthy Future Act of 2009 H.R.3962 Affordable Health Care for America Act H.R.3590 Patient Protection and Affordable Care Act H.R.4872 Health Care and Education Reconciliation Act of 2010 S 75 - Generics First Act 2009 S 301 - Physician Payments Sunshine Act of 2009 H.R.759 Food and Drug Administration Globalization Act of 2009 HR 276 - Proper Disposal of Unused Pharmaceuticals S1213 Patient-Centered Outcomes Research Act of 2009 HR 4702, HR 4990 - A bill to amend title XIX of the Social Security Act to include all public clinics for the distribution of pediatric vaccines under the Medicaid program. HR 4705 HR 4993, S 2466 - Vaccines for the uninsured Adult Act of 2008 HR 1259 Dextromethorphan Distribution Act of 2009 S 1383 Dextromethorphan Abuse Reduction Act of 2009 S 256 Combat Methamphetamine Enhancement Act of 2009 HR 2923 Combat Methamphetamine Enhancement Act of 2009 HR 1038, S623 - Access to Life-Saving Medicine Act HR 1548 Pathway for Biosimilars Act HR 1427 - Promoting Innovation and Access to Life-Saving Medicine Act S 726 - Promoting Innovation and Access to Life-Saving Medicine Act S.1232 - Pharmaceutical Market Access and Drug Safety Act of 2009 HR 1548 - To amend the Public Health Service Act to establish a pathway for the licensure of biosimilar biological products, and for other purposes S 525 - Pharmaceutical Market Access and Drug Safety Act of 2009 21st Century Cancer Bill Personalized Medicine Public Health Service Act Drug Importation Gene Therapy PDUFA
Client expense: $1,000,000 · Firm income: Not reported
H.R.3200 America's Affordable Health Choices Act of 2009 S.1796 America's Healthy Future Act of 2009 H.R.3962 Affordable Health Care for America Act H.R.3590 Patient Protection and Affordable Care Act H.R.4872 Health Care and Education Reconciliation Act of 2010 S 75 - Generics First Act 2009 S 301 - Physician Payments Sunshine Act of 2009 H.R.759 Food and Drug Administration Globalization Act of 2009 HR 276 - Proper Disposal of Unused Pharmaceuticals S1213 Patient-Centered Outcomes Research Act of 2009 HR 4702, HR 4990 - A bill to amend title XIX of the Social Security Act to include all public clinics for the distribution of pediatric vaccines under the Medicaid program. HR 4705 HR 4993, S 2466 - Vaccines for the uninsured Adult Act of 2008 HR 1259 Dextromethorphan Distribution Act of 2009 S 1383 Dextromethorphan Abuse Reduction Act of 2009 S 256 Combat Methamphetamine Enhancement Act of 2009 HR 2923 Combat Methamphetamine Enhancement Act of 2009 HR 1038, S623 - Access to Life-Saving Medicine Act HR 1548 Pathway for Biosimilars Act HR 1427 - Promoting Innovation and Access to Life-Saving Medicine Act S 726 - Promoting Innovation and Access to Life-Saving Medicine Act S.1232 - Pharmaceutical Market Access and Drug Safety Act of 2009 HR 1548 - To amend the Public Health Service Act to establish a pathway for the licensure of biosimilar biological products, and for other purposes S 525 - Pharmaceutical Market Access and Drug Safety Act of 2009 21st Century Cancer Bill Personalized Medicine Public Health Service Act Drug Importation Gene Therapy PDUFA
Client expense: $1,842,000 · Firm income: Not reported
H.R.3200 America's Affordable Health Choices Act of 2009 S.1796 America's Healthy Future Act of 2009 H.R.3962 Affordable Health Care for America Act H.R.3590 Patient Protection and Affordable Care Act H.R.4872 Health Care and Education Reconciliation Act of 2010 S 75 - Generics First Act 2009 S 301 - Physician Payments Sunshine Act of 2009 H.R.759 Food and Drug Administration Globalization Act of 2009 HR 276 - Proper Disposal of Unused Pharmaceuticals S1213 Patient-Centered Outcomes Research Act of 2009 HR 4702, HR 4990 - A bill to amend title XIX of the Social Security Act to include all public clinics for the distribution of pediatric vaccines under the Medicaid program. HR 4705 HR 4993, S 2466 - Vaccines for the uninsured Adult Act of 2008 HR 1259 Dextromethorphan Distribution Act of 2009 S 1383 Dextromethorphan Abuse Reduction Act of 2009 S 256 Combat Methamphetamine Enhancement Act of 2009 HR 2923 Combat Methamphetamine Enhancement Act of 2009 HR 1038, S623 - Access to Life-Saving Medicine Act HR 1548 Pathway for Biosimilars Act HR 1427 - Promoting Innovation and Access to Life-Saving Medicine Act S 726 - Promoting Innovation and Access to Life-Saving Medicine Act S.1232 - Pharmaceutical Market Access and Drug Safety Act of 2009 HR 1548 - To amend the Public Health Service Act to establish a pathway for the licensure of biosimilar biological products, and for other purposes S 525 - Pharmaceutical Market Access and Drug Safety Act of 2009 21st Century Cancer Bill Personalized Medicine Public Health Service Act Drug Importation Gene Therapy PDUFA
Client expense: $1,616,000 · Firm income: Not reported
H.R.3200 America's Affordable Health Choices Act of 2009 S.1796 America's Healthy Future Act of 2009 H.R.3962 Affordable Health Care for America Act H.R.3590 Patient Protection and Affordable Care Act H.R.4872 Health Care and Education Reconciliation Act of 2010 S 75 - Generics First Act 2009 S 301 - Physician Payments Sunshine Act of 2009 H.R.759 Food and Drug Administration Globalization Act of 2009 HR 276 - Proper Disposal of Unused Pharmaceuticals S1213 Patient-Centered Outcomes Research Act of 2009 HR 4702, HR 4990 - A bill to amend title XIX of the Social Security Act to include all public clinics for the distribution of pediatric vaccines under the Medicaid program. HR 4705 HR 4993, S 2466 - Vaccines for the uninsured Adult Act of 2008 HR 1259 Dextromethorphan Distribution Act of 2009 S 1383 Dextromethorphan Abuse Reduction Act of 2009 S 256 Combat Methamphetamine Enhancement Act of 2009 HR 2923 Combat Methamphetamine Enhancement Act of 2009 HR 1038, S623 - Access to Life-Saving Medicine Act HR 1548 Pathway for Biosimilars Act HR 1427 - Promoting Innovation and Access to Life-Saving Medicine Act S 726 - Promoting Innovation and Access to Life-Saving Medicine Act S.1232 - Pharmaceutical Market Access and Drug Safety Act of 2009 HR 1548 - To amend the Public Health Service Act to establish a pathway for the licensure of biosimilar biological products, and for other purposes S 525 - Pharmaceutical Market Access and Drug Safety Act of 2009 21st Century Cancer Bill Personalized Medicine Public Health Service Act Drug Importation Gene Therapy PDUFA
Client expense: $2,040,000 · Firm income: Not reported
| Republican |
| MN |
| Patrick J. Leahy | Democratic | VT |
| Sherrod Brown | Democratic | OH |
| Susan M. Collins | Republican | ME |
Government targets: Commerce, Dept of (DOC), Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, U.S. Agency for International Development (USAID), U.S. Trade Representative (USTR)
Government targets: Commerce, Dept of (DOC), Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, U.S. Agency for International Development (USAID), U.S. Trade Representative (USTR)
Government targets: Commerce, Dept of (DOC), Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, U.S. Agency for International Development (USAID), U.S. Trade Representative (USTR)
Government targets: Commerce, Dept of (DOC), Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, U.S. Agency for International Development (USAID), U.S. Trade Representative (USTR)
2009 · first_quarter · Health Issues
H.R. 1 The American Recovery and Reinvestment Act, S. 301 Physician Payment Sunshine Act, S. 537 Sunshine in Litigation Act, S. 623 The Pre-existing Condition Patient Protection Act, H.R. 427 Promoting Innovation and Access to Life-Saving Medicine Act, HR 1548 Pathway for Biosimilars Act, S. 726 Licensing of Biosimilar/Biogeneric Products, general comparative effectiveness issues, general health reform and the un/underinsured, general diabetes legislation
Client expense: $450,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2009 · fourth_quarter · Copyright/Patent/Trademark
Issues relating to patent law and patent procedure: S. 1145 and H.R. 1908 (Patent Reform Act of 2007), S. 623 (Access to Life-Saving Medicine Act), H.R. 5629 (Pathways and Biosimilars Act)
Client expense: Not reported · Firm income: $30,000
Government targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO), SENATE
2009 · fourth_quarter · Health Issues
S. 301 Physician Payment Sunshine Act, S. 537 Sunshine in Litigation Act, S. 623 The Pre-existing Condition Patient Protection Act, H.R. 427 Promoting Innovation and Access to Life-Saving Medicine Act, H.R. 1548 Pathway for Biosimilars Act, S. 726 Licensing of Biosimilar/Biogeneric Products, general comparative effectiveness issues, general health reform and the un/underinsured, general diabetes legislation, S 1679 Affordable Health Choices Act; HR 3961Medicare Physician Payment Reform Act of 2009; S 1796 America's Healthy Future Act of 2009; HR 3962 Affordable Health Care for America Act; HR 3590 Senate Leadership's Health Care Overhaul; H.R. 1995 Eliminating Disparities in Diabetes Prevention Access and Care Act of 2009, FTC Report "Emerging Health Care Issues: Follow-on Bilogic Drug Competition," mental health parity, value based insurance design, quality of care, adhereance.
Client expense: $465,000 · Firm income: Not reported
Government targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), Medicare Payment Advisory Commission (MedPAC), SENATE
Vaccines for Children Program Vaccines for Adults Coverage Provide Medicare Part B Coverage for Vaccines Currenlty Under Part D Medicaid Coverage of Vaccines HR 3200 America's Affordable Health Choices Act of 2009 HR 2502 Comparative Effectiveness Research Act of 2009 S 75 - Generics First Act 2009 S 301 - Physician Payments Sunshine Act of 2009 HR 276 - Proper Disposal of Unused Pharmaceuticals S1213 Patient-Centered Outcomes Research Act of 2009 HR 4702, HR 4990 - A bill to amend title XIX of the Social Security Act to include all public clinics for the distribution of pediatric vaccines under the Medicaid program. HR 4705 HR 4993, S 2466 - Vaccines for the uninsured Adult Act of 2008 S 2467 - Vaccine shortage preparedness Act of 2008 S 3678 - /PL 109-417 All pandemic and all-hazards act - Section 317 program issues HR 1259 Dextromethorphan Distribution Act of 2009 S 1383 Dextromethorphan Abuse Reduction Act of 2009 S 256 Combat Methamphetamine Enhancement Act of 2009 HR 2923 Combat Methamphetamine Enhancement Act of 2009 HR 1038, S623 - Access to Life-Saving Medicine Act HR 1548 Pathway for Biosimilars Act HR 1427 - Promoting Innovation and Access to Life-Saving Medicine Act S 726 - Promoting Innovation and Access to Life-Saving Medicine Act S.1232 - Pharmaceutical Market Access and Drug Safety Act of 2009 HR 1548 - To amend the Public Health Service Act to establish a pathway for the licensure of biosimilar biological products, and for other purposes S 525 - Pharmaceutical Market Access and Drug Safety Act of 2009 21st Century Cancer Bill Personalized Medicine Public Health Service Act Drug Importation Gene Therapy Direct to Consumer Advertising Drug Safety Legislation Global Hypertension
Client expense: $1,570,000 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE, U.S. Agency for International Development (USAID)
2009 · third_quarter · Copyright/Patent/Trademark
Issues relating to patent law and patent procedure; S. 1145 and HR. 1908 (Patent Reform Act of 2007), S. 623 (Access to Life-Saving Medicine Act), HR. 5629 (Pathways and Biosimilars Act)
Client expense: Not reported · Firm income: $30,000
Government targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO), SENATE
2009 · third_quarter · Copyright/Patent/Trademark
Issues relating to patent law and patent procedure; S. 1145 and HR. 1908 (Patent Reform Act of 2007), S. 623 (Access to Life-Saving Medicine Act), HR. 5629 (Pathways and Biosimilars Act)
Client expense: Not reported · Firm income: $30,000
Government targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO), SENATE
2009 · third_quarter · Copyright/Patent/Trademark
Issues relating to patent law and patent procedure; S. 1145 and HR. 1908 (Patent Reform Act of 2007), S. 623 (Access to Life-Saving Medicine Act), HR. 5629 (Pathways and Biosimilars Act)
Client expense: Not reported · Firm income: $30,000
Government targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO), SENATE
2009 · third_quarter · Copyright/Patent/Trademark
H.R. 1260 Patent Reform S. 515 Patent Reform S. 610 Patent Reform H. R. 1909 Intellectual Property and Process Patent Issues S. 1145/H.R. 1908; Patent Reform Act of 2007 S. 623 Access to Life-Saving Medicine Act H.R. 5629 Pathways and Biosimilars Act
Client expense: $630,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2009 · third_quarter · Copyright/Patent/Trademark
Issues relating to patent law and patent procedure; S. 1145 and HR. 1908 (Patent Reform Act of 2007), S. 623 (Access to Life-Saving Medicine Act), HR. 5629 (Pathways and Biosimilars Act)
Client expense: Not reported · Firm income: $30,000
Government targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO), SENATE
2009 · third_quarter · Health Issues
S.- America's Healthy Future Act. (Finance Committee Version); S. 1679- The Affordable Health Choices Act; H.R. 3200: America's Affordable Health Choices Act of 2009; H.R. 1298, Pharmaceutical Market Access and Drug Safety Act of 2009: importation; H.R. 1427, Promoting Innovation and Access to Life-Saving Medicine Act: regulatory approval pathway for follow-on biologics; H.R. 1548, Pathway for Biosimilars Act: regulatory approval pathway for follow-on biologics; H.R. 2502, Comparative Effectiveness Research Act of 2009: comparative effectiveness; S. 488, Access to Cancer Clinical Trials Act of 2009, access to clinical trials; S. 525, Pharmaceutical Market Access and Drug Safety Act of 2009: importation; S. 726, Promoting Innovation and Access to Life-Saving Medicine Act: regulatory approval pathway for follow-on biologics; S. 1142, Informed Health Care Decision Making Act: drug labeling; S. 1213, Patient-Centered Outcomes and Research Act of 2009: comparative effectiveness; S. 1232, Pharmaceutical Market Access and Drug Safety Act of 2009: importation; S. 1679, Affordable Health Choices Act: health reform, regulatory pathway for follow-on biologics, 340B program issues; H.R. 759, Food and Drug Administration Globalization Act, 2009: import safety; S. 623, Access to Life-Saving Medicine Act; Follow-on biologics
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
Vaccines for Children Program Vaccines for Adults Coverage Provide Medicare Part B Coverage for Vaccines Currenlty Under Part D Medicaid Coverage of Vaccines HR 3200 America's Affordable Health Choices Act of 2009 HR 2502 Comparative Effectiveness Research Act of 2009 S 75 - Generics First Act 2009 S 301 - Physician Payments Sunshine Act of 2009 HR 276 - Proper Disposal of Unused Pharmaceuticals S1213 Patient-Centered Outcomes Research Act of 2009 HR 4702, HR 4990 - A bill to amend title XIX of the Social Security Act to include all public clinics for the distribution of pediatric vaccines under the Medicaid program. HR 4705 HR 4993, S 2466 - Vaccines for the uninsured Adult Act of 2008 S 2467 - Vaccine shortage preparedness Act of 2008 S 3678 - /PL 109-417 All pandemic and all-hazards act - Section 317 program issues HR 1259 Dextromethorphan Distribution Act of 2009 S 1383 Dextromethorphan Abuse Reduction Act of 2009 S 256 Combat Methamphetamine Enhancement Act of 2009 HR 2923 Combat Methamphetamine Enhancement Act of 2009 HR 1038, S623 - Access to Life-Saving Medicine Act HR 1548 Pathway for Biosimilars Act HR 1427 - Promoting Innovation and Access to Life-Saving Medicine Act S 726 - Promoting Innovation and Access to Life-Saving Medicine Act S.1232 - Pharmaceutical Market Access and Drug Safety Act of 2009 HR 1548 - To amend the Public Health Service Act to establish a pathway for the licensure of biosimilar biological products, and for other purposes S 525 - Pharmaceutical Market Access and Drug Safety Act of 2009 21st Century Cancer Bill Personalized Medicine Public Health Service Act Drug Importation Gene Therapy Direct to Consumer Advertising Drug Safety Legislation Global Hypertension
Client expense: $1,420,000 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE, U.S. Agency for International Development (USAID)
2009 · second_quarter · Health Issues
Affordable Health Choice Act. S301 Physician Payments Sunshine Act 2009. HR380, S623, Access to Life-Saving Medicine Act; Follow-on biologics, importation, HR3610 Food and Drug Safety Act of 2007: Import safety; HR5839, Safeguard Americans Pharmaceuticals Act; S2029, Physician's Payment Sunshine Act; Reporting periodicity, pre-emption. HR1427 and HR1038, Access to Life-Saving Medicine Act; follow-on biologics; HR1956, Patient Protection and Innovative Biologic Medicines Act of 2007; follow-on biologics; HR3610, Food and Drug Import Safety Act of 2007; Import safety HR 6151, Responsibilty in Drug and Device Advertising Act of 2008: Direct-to-consumer advertising; S 242, Pharmaceutical Market Acess and Drug Safety Act of 2007: importation; S 334, Healthy Americans Act: non-interference; S. 1693, Wired for Health Care Quality Act: health information technology and health care quality and costs; S 1695, Biologics Price Competition and Innovation Act of 2007: follow-on biologics; S 2663, CPSC Reform Act: importation; S 3398, Medical Device Safety Act of 2008: preemption issues; S 3409, Drug and Device Accountability Act of 2008: import safety
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
Vaccines for Children Program Vaccines for Adults Coverage Provide Medicare Part B Coverage for Vaccines Currenlty Under Part D Medicaid Coverage of Vaccines HR 3200 America's Affordable Health Choices Act of 2009 S 75 - Generics First Act 2009 S 301 - Physician Payments Sunshine Act of 2009 HR 276 - Proper Disposal of Unused Pharmaceuticals HR 2502 Comparative Effectiveness Research Act of 2009 S1213 Patient-Centered Outcomes Research Act of 2009 HR 4702, HR 4990 - A bill to amend title XIX of the Social Security Act to include all public clinics for the distribution of pediatric vaccines under the Medicaid program. HR 4705 HR 4993, S 2466 - Vaccines for the uninsured Adult Act of 2008 S 2467 - Vaccine shortage preparedness Act of 2008 S 3678 - /PL 109-417 All pandemic and all-hazards act - Section 317 program issues HR 1259 Dextromethorphan Distribution Act of 2009 S 1383 Dextromethorphan Abuse Reduction Act of 2009 S 256 Combat Methamphetamine Enhancement Act of 2009 HR 2923 Combat Methamphetamine Enhancement Act of 2009 HR 1038, S623 - Access to Life-Saving Medicine Act HR 1548 Pathway for Biosimilars Act HR 1427 - Promoting Innovation and Access to Life-Saving Medicine Act S 726 - Promoting Innovation and Access to Life-Saving Medicine Act HR 1548 - To amend the Public Health Service Act to establish a pathway for the licensure of biosimilar biological products, and for other purposes 21st Century Cancer Bill Personalized Medicine Public Health Service Act Drug Importation Gene Therapy Direct to Consumer Advertising Drug Safety Legislation Global Hypertension
Client expense: $1,808,536 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE, U.S. Agency for International Development (USAID)
2009 · second_quarter · Pharmacy
Access to Life-Saving Medicine Act (H.R. 1038 & S. 623), Affordable Biologics for Consumers Act (S. 1505), Biologics Price Competition and Innovation Act of 2007 (S. 1695), Consumer Food Safety Act of 2008 (H.R. 3624), Fair Prescription Drug Competition Act (H.R. 806 & S. 438), Food and Drug Import Safety Act of 2007 (H.R. 3610, The Pathway for Biologics Act (H.R. 5629), The Patient Protection and Innovative Biologic Medicines Act (H.R. 1956).
Client expense: Not reported · Firm income: $40,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2009 · second_quarter · Copyright/Patent/Trademark
Issues relating to patent law and patent procedure; S. 1145 and HR. 1908 (Patent Reform Act of 2007), S. 623 (Access to Life-Saving Medicine Act), HR. 5629 (Pathways and Biosimilars Act)
Client expense: Not reported · Firm income: $30,000
Government targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO), SENATE
2009 · first_quarter · Health Issues
HR 2 Children's Health Insurance Program Reauthorization Act 2009. S301 Physician Payments Sunshine Act 2009. HR380, S623, Access to Life-Saving Medicine Act; Follow-on biologics, importation, HR3610 Food and Drug Safety Act of 2007: Import safety; HR5839, Safeguard Americans Pharmaceuticals Act; S2029, Physician's Payment Sunshine Act; Reporting periodicity, pre-emption. HR1427 and HR1038, Access to Life-Saving Medicine Act; follow-on biologics; HR1956, Patient Protection and Innovative Biologic Medicines Act of 2007; follow-on biologics; HR3610, Food and Drug Import Safety Act of 2007; Import safety HR 6151, Responsibilty in Drug and Device Advertising Act of 2008: Direct-to-consumer advertising; S 242, Pharmaceutical Market Acess and Drug Safety Act of 2007: importation; S 334, Healthy Americans Act: non-interference; S. 1693, Wired for Health Care Quality Act: health information technology and health care quality and costs; S 1695, Biologics Price Competition and Innovation Act of 2007: follow-on biologics; S 2663, CPSC Reform Act: importation; S 3398, Medical Device Safety Act of 2008: preemption issues; S 3409, Drug and Device Accountability Act of 2008: import safety
Client expense: Not reported · Firm income: $60,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2009 · first_quarter · Copyright/Patent/Trademark
S. 515, H.R. 1260 Patent Reform Act of 2009 H.R. 1427, S. 726 Promoting Innovation and Access to Life-Saving Medicine Act H.R. 1548 Pathway for Biosimilars Act S. 623 Access to Life Saving Medicine Act
Client expense: $520,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
2009 · first_quarter · Health Issues
Issues relating to antibiotic exclusivity; S. 501 - Fair Prescription Drug Competition Act; H.R. 573 - Relating to marketing of authorized generic drugs; H.R. 1548 - The Pathway to Biosimilars Act; S. 623 & H.R. 1427 - The Promoting Innovation and Access to Life- Savings Medicine Act
Client expense: Not reported · Firm income: $40,000
Government targets: Federal Trade Commission (FTC), HOUSE OF REPRESENTATIVES, SENATE
2009 · first_quarter · Health Issues
H.R. 1 The American Recovery and Reinvestment Act, S. 301 Physician Payment Sunshine Act, S. 537 Sunshine in Litigation Act, S. 623 The Pre-existing Condition Patient Protection Act, H.R. 427 Promoting Innovation and Access to Life-Saving Medicine Act, HR 1548 Pathway for Biosimilars Act, S. 726 Licensing of Biosimilar/Biogeneric Products, general comparative effectiveness issues, general health reform and the un/underinsured, general diabetes legislation
Client expense: $375,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
HR 4703, S 2467, HR 4991 - Vaccine Shortage preparedness Act of 2008 S 2464, HR 4992, HR 4704 - A bill to amend title XVIII of the Social Security Act to provide for coverage of federally recommended vaccines under Medicare Part B S 2465 - Vaccines for Children Access Act of 2008 HR 2 - Children's Health Insurance Program Reauthorization Act of 2009 S 75 - Generics First Act 2009 S 80 - Importation of Prescription Drugs S 301 - Physician Payments Sunshine Act of 2009 HR 276 - Proper Disposal of Unused Pharmaceuticals HR 5839 - Safeguarding America's Pharmaceuticals Act of 2008 S 3408 - Comparative Effectiveness Research Act of 2008 HR 4702, HR 4990 - A bill to amend title XIX of the Social Security Act to include all public clinics for the distribution of pediatric vaccines under the Medicaid program. HR 4705 HR 4993, S 2466 - Vaccines for the uninsured Adult Act of 2008 S 2467 - Vaccine shortage preparedness Act of 2008 S 3678 - /PL 109-417 All pandemic and all-hazards act - Section 317 program issues HR 970 and S 1378 - Dextromethorphan Distribution Act of 2007 S 103 - Combat Meth Act of 2005 HR 2207 - Agricultural Disaster Assistance and Western States Emergency - Unfinished business Appropriations Act of 2007 HR 1908 and S 1710 Patent Reform Act of 2007 HR 1 - Implementing the 9/11 Commission recommendations Act of 2007 HR 3162 - Children's Health and Medicare Protection Act of 2007 S 1505 - Affordable Biologics for Consumers Act S 1695 - Biologics Price Competition and Innovation Act of 2007 HR 1956 - Patent Protection and Innovative Biologic Medicines Act of 2007 HR 1038, S623 - Access to Life-Saving Medicine Act HR 4083 - Non-prescription Drug Modernization Act of 2007 HR 1308 - Legal Immigrant Children's Health Improvement Act of 2007 HR 5629 - Pathway for Biosimilars Act HR 1427 - To amend the Public Health Service Act to provide for the licensing of biosimilar and biogeneric biological products, and for other purposes S 726 - A bill to amend the Public Health Service Act to provide for the licensing of biosimilar and biogeneric biological products, and for other purposes HR 1548 - To amend the Public Health Service Act to establish a pathway for the licensure of biosimilar biological products, and for other purposes Comparative Effectiveness Research Public Health Service Act Drug Importation Gene Therapy Direct to Consumer Advertising Drug Safety Legislation Global Hypertension
Client expense: $1,347,134 · Firm income: Not reported
Government targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE, U.S. Agency for International Development (USAID)
2009 · first_quarter · Copyright/Patent/Trademark
Issues relating to patent law and patent procedure; S. 1145 and HR. 1908 (Patent Reform Act of 2007), S. 623 (Access to Life-Saving Medicine Act), HR. 5629 (Pathways to Biosimilars Act)
Client expense: Not reported · Firm income: $30,000
Government targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO), SENATE
2009 · first_quarter · Copyright/Patent/Trademark
H.R. 1956, Patent Protection and Innovative Biologic Medicines Act of 2007, S.1695, Biologics Price Competition and Innovation Act of 2007, H.R. 1038, S.623, Access to Life-Saving Medicine Act, H.R. 1908, S.1145, Patent Reform Act of 2007
Client expense: Not reported · Firm income: $6,500
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2008 · fourth_quarter · Science/Technology
S.1082/H.R. 2900 - Food and Drug Revitalization Act: to provide for reasonable limits for conflicts of interest on FDA advisory committees and to stimulate pediatric device development. Also, to include unique device identification systems for medical devices. H.R. 2900/S.1082 - Food and Drug Amendments Act of 2007: to provide for reasonable limits for conflicts of interest on FDA advisory committees and to stimulate pediatric device development. Also, to provide unique identification systems for medical devices. S.830/H.R. 1494 - Pediatric Medical Devices Safety and Improvement Act: to stimulate development of necessary medical devices for the pediatric population. H.R. 1956/H.R. 5629/H.R. 1038/S.623 - Regulation Devices Biologics and Combination Products by the FDA: to provide a pathway for follow-on biologics that would not allow for interchangeability without express physician approval. The Food and Drug Administration Globalization Act of 2008: to provide for the safety of medical devices manufactured in foreign countries. H.R. 6381 - Medical Device Safety Act of 2008: to amend the Food, Drug and Cosmetic Act with respect to liability under state and local requirements for medical devices.
Client expense: $365,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Medicare Payment Advisory Commission (MedPAC), SENATE
2008 · second_quarter · Medicare/Medicaid
Medicare (HR 6331), Follow-on Biologics (HR 5629, HR 1956, S 623, S 1695, S 1505, HR 1038)
Client expense: $2,860,000 · Firm income: Not reported
Government targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Security Council (NSC), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
2008 · second_quarter · Copyright/Patent/Trademark
Norway IP, Finland IP, Poland (IP), Russa WTO accession (IP), Spain IP, Japan (IP), Korea FTA (IP), China (counterfeiting, IP), ASEAN (regulatory harmonization), Thailand (CLs), Philippines (IP), Intellectual Property Rights Enforcement Act (S. 522), Patent Reform Act (S 1145 & HR 1908), Canada (IP), Mexico (IP), Brazil (IP), Canada Market Access & Drug Safety (S 242), Algeria and Tunisia (IP), Egypt (IP), Saudi Arabia (IP), Per (FTA implementation), Argentina (IP), Chili (IP), European Union (market access) Follow-on biologics (HR 5629, HR 1956, S 623, S 1695, S 1505, HR 1038), IP Rights Enforcement Act (S 522)
Client expense: $2,860,000 · Firm income: Not reported
Government targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Security Council (NSC), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
2008 · second_quarter · Economics/Economic Development
Follow-on Biologics (HR 5629, HR 1956, S 623, S 1695, S 1505, HR 1038), Patent Reform (HR 1908, S 1145)
Client expense: $2,860,000 · Firm income: Not reported
Government targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Security Council (NSC), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
2008 · second_quarter · Health Issues
Access for uninsured (S 1886 & S 1975), Biosimilares (S 1695 & HR 5629), health care reform, United Kingdom (pricing reform), Italy (health care reform & pricing), Germany (health care reform & pricing), France (health care reform & pricing), funding to fight tuberculosis (HR 5501, S 2731), Follow-on Biologics (S 623 & HR 1956), FDA Reauthorization (HR 3580), Medicare Reimbursement (HR 6331), Patent Reform (HR 1908, S 1145)
Client expense: $2,860,000 · Firm income: Not reported
Government targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Security Council (NSC), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
2008 · second_quarter · Medical/Disease Research/Clinical Labs
Pending draft oncology, Follow-on biologics (HR 5629, HR 1956, S 623, S 1695, S 1505, HR 1038), Patent Reform (HR 1908, S 1145)
Client expense: $2,860,000 · Firm income: Not reported
Government targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Security Council (NSC), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
2008 · second_quarter · Medical/Disease Research/Clinical Labs
Pending draft oncology, Follow-on biologics (HR 5629, HR 1956, S 623, S 1695, S 1505, HR 1038), Patent Reform (HR 1908, S 1145)
Client expense: $2,860,000 · Firm income: Not reported
Government targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Security Council (NSC), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
2008 · second_quarter · Medicare/Medicaid
Medicare (HR 6331), Follow-on Biologics (HR 5629, HR 1956, S 623, S 1695, S 1505, HR 1038)
Client expense: $2,860,000 · Firm income: Not reported
Government targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Security Council (NSC), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
2008 · second_quarter · Copyright/Patent/Trademark
Norway IP, Finland IP, Poland (IP), Russa WTO accession (IP), Spain IP, Japan (IP), Korea FTA (IP), China (counterfeiting, IP), ASEAN (regulatory harmonization), Thailand (CLs), Philippines (IP), Intellectual Property Rights Enforcement Act (S. 522), Patent Reform Act (S 1145 & HR 1908), Canada (IP), Mexico (IP), Brazil (IP), Canada Market Access & Drug Safety (S 242), Algeria and Tunisia (IP), Egypt (IP), Saudi Arabia (IP), Per (FTA implementation), Argentina (IP), Chili (IP), European Union (market access) Follow-on biologics (HR 5629, HR 1956, S 623, S 1695, S 1505, HR 1038), IP Rights Enforcement Act (S 522)
Client expense: $2,860,000 · Firm income: Not reported
Government targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Security Council (NSC), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
2008 · second_quarter · Health Issues
Access for uninsured (S 1886 & S 1975), Biosimilares (S 1695 & HR 5629), health care reform, United Kingdom (pricing reform), Italy (health care reform & pricing), Germany (health care reform & pricing), France (health care reform & pricing), funding to fight tuberculosis (HR 5501, S 2731), Follow-on Biologics (S 623 & HR 1956), FDA Reauthorization (HR 3580), Medicare Reimbursement (HR 6331), Patent Reform (HR 1908, S 1145)
Client expense: $2,860,000 · Firm income: Not reported
Government targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Security Council (NSC), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
2008 · second_quarter · Economics/Economic Development
Follow-on Biologics (HR 5629, HR 1956, S 623, S 1695, S 1505, HR 1038), Patent Reform (HR 1908, S 1145)
Client expense: $2,860,000 · Firm income: Not reported
Government targets: Agriculture, Dept of (USDA), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Security Council (NSC), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
2008 · fourth_quarter · Pharmacy
S. 877, Controlling the Abuse of Prescriptions Act of 2007 Drug importation H. R. 1038, Access to Life-Saving Medicine Act, follow-on biologics H. R. 1956, Patient Protection and Innovative Biologic Medicines Act of 2007, follow-on biologics H. R. 5629, Pathway for Biosimilars Act S. 1505, Affordable Biologics for Consumers Act of 2007, follow-on biologics S. 1695, Biologics Price Competition and Innovation Act of 2007, follow-on biologics S. 2029, Physician Payments Sunshine Act of 2007 S. 623, Access to Life-Saving Medicine Act, follow-on biologics
Client expense: Not reported · Firm income: $50,000
Government targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Patent & Trademark Office (PTO), SENATE
2008 · fourth_quarter · Copyright/Patent/Trademark
H.R.1908, S.1145 Patent Reform Act of 2007 H.R.806 To Amend the FD&C Act to Prohibit the Marketing of Authorized Generics S.438 Fair Prescription Drug Competition Act H.R.1038, S.623 Access to Life Saving Medicines Act H.R.1956 Patient Protection and Innovative Biologic Medicines Act of 2007 H.R.5629 Pathway for Biosimilars Act H.R.1902 Protecting Consumers Access to Generic Drugs Act of 2007 S.316 Preserve Access to Affordable Generics Act
Client expense: $150,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
2008 · fourth_quarter · Medical/Disease Research/Clinical Labs
S. 623 Access to Lifesaving Medicine Act H.R. 1038 Access to Lifesaving Medicine Act H.R. 1956 Patient Protection and Innovative Biologic Medicine Act of 2007 S. 1695 Biologics Price Competition and Innovation Act of 2007 S. 1505 Affordable Biologics for Consumer Act H.R. 5629 Pathway for Biosimilars Act
Client expense: $2,000,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2008 · fourth_quarter · Pharmacy
Issues that relate to legislation addressing the FDA, Bioshield, and generic biologics; S.623/H.R. 1032, Access to Life Saving Medicine Act
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2008 · fourth_quarter · Medical/Disease Research/Clinical Labs
S. 623 Access to Lifesaving Medicine Act H.R. 1038 Access to Lifesaving Medicine Act H.R. 1956 Patient Protection and Innovative Biologic Medicine Act of 2007 S. 1695 Biologics Price Competition and Innovation Act of 2007 S. 1505 Affordable Biologics for Consumer Act H.R. 5629 Pathway for Biosimilars Act
Client expense: $2,000,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2008 · first_quarter · Health Issues
Access for uninsured (S 1886 & S 1975), Biosimilars (S 1695 & HR 5629), healthcare reform, United Kingdom (pricing reform), Italy (healthcare reform & pricing), Germany (healthcare reform & pricing), France (healthcare reform & pricing), funding to fight tuberculosis (HR 5501, S 2731, S 968, HR 1567), Follow-on biologics (S 623 & HR 1956)
Client expense: $2,895,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Justice, Dept of (DOJ), Natl Security Agency (NSA), Natl Security Council (NSC), Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), U.S. Trade Representative (USTR)
2008 · fourth_quarter · Health Issues
Generic Biologics (S. 623; S. 1695; H.R. 1038); Health system / insurance / ERISA reform (H.R. 676; H.R. 506; H.R. 2034; H.R. 3163; S. 334; S. 1783; S. 1019; S. 2818; S. 1886; S. 2795; H.R. 6210); Health cost savings / comparative effectiveness / wellness promotion (H.R. 2184; H.R. 3162; S. 1342; S. 1753; S. 1754; H.R. 3717; H.R. 853; H.R. 2633; S. 3408); Health IT (S. 1693; H.R. 5442; H.R. 6357; H.R. 6898); High Risk Pools (S. 3230, Labor-HHS Approps.); Medicare (Medicare Advantage, electronic prescribing, sales and marketing of Medicare private insurance products (H.R. 3162, S 3101, HR 6331, HR 4296, S. 2408); medcal liability reform (S. 243, S 2662, HR 2580, HR 5480, insurance regulation (S 40, HR 5611, HR 5840), long term care (S 1758, S 2337, HR 3363); SCHIP reauthorization (HR 976, HR 3963); Health insurance tax treatment (HRAs, HSAs, FSAs, Health Care Tax Credit--HR 3920, HR 3943, HR 4341, S 1739, S 1848, HR 5719); Small business / national pooling of insurance health reform (S. 2795; H.R. 6210; H.R. 6582)
Client expense: $250,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2008 · fourth_quarter · Health Issues
Generic Biologics (s. 623; S. 1695; H.R. 1038); Health system/Insurance/ ERISA reform (H.R. 676; H.R. 506; H.R. 2034; H.R. 3163; S. 334; S. 1783; S. 1019; S. 2818; S. 1886; S. 2795; H.R. 6210); Health cost savings/comparative effectiveness/wellness promotion (H.R. 2184; H.R. 3162; S. 1342; S. 1753; S. 1754; S. 3408; H.R. 3717; H.R. 853; H.R. 2633); Health IT (S. 1693; H.R. 5442; H.R. 6357; H.R. 6898); High risk pools (S. 3230, Labor HHS Approps.); Medicare (Medicare Advantage, electronic prescribing, sales and marketing of Mediare-related private insurance products - H.R. 3162; S. 3101; H.R. 6331; H.R. 4296; s. 2408); medical liability reform (S. 243; S. 2662; H.R. 2580; H.R. 5480); insurance regulation (S. 40; H.R. 5611; H.R. 5840); Long term care (S. 2337, S. 1758; H.R. 3363); SCHIP reauthorization (H.R. 976); Health Insurance Tax Treatment (HSAs, FSAs, HRAs, Health Coverage Tax Credit - H.R. 3920; H.R. 3943; H.R. 4341; S. 1739; S. 1848; H.R. 5719); small business/national pooling of insurance health reform (s. 2795; H.R. 6210; H.R. 6582)
Client expense: $250,000 · Firm income: Not reported
Government targets: Administration on Aging, Agency for Healthcare Research & Quality (AHRQ), Centers For Medicare and Medicaid Services (CMS), Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
2008 · fourth_quarter · Health Issues
Generic Biologics (S. 623; S. 1695; H.R. 1038); Health system / insurance / ERISA reform (H.R. 676; H.R. 506; H.R. 2034; H.R. 3163; S. 334; S. 1783; S. 1019; S. 2818; S. 1886; S. 2795; H.R. 6210); Health cost savings / comparative effectiveness / wellness promotion (H.R. 2184; H.R. 3162; S. 1342; S. 1753; S. 1754; H.R. 3717; H.R. 853; H.R. 2633; S. 3408); Health IT (S. 1693; H.R. 5442; H.R. 6357; H.R. 6898); High Risk Pools (S. 3230, Labor-HHS Approps.); Medicare (Medicare Advantage, electronic prescribing, sales and marketing of Medicare-related private insurance products H.R. 3162; S. 3101; H.R. 6331; H.R. 4296; S. 2408); medical liability reform (S. 243; S. 2662; H.R. 2580; H.R. 5480); insurance regulation (S. 40; H.R. 5611; H.R. 5840); Long Term Care (S. 1758; S. 2337; H.R. 3363); SCHIP reauthorization (H.R. 976; H.R. 3963); Health Insurance Tax Treatment (HSAs, FSAs, HRAs, Health Coverage Tax Credit H.R. 3920; H.R. 3943; H.R. 4341; S. 1739; S. 1848; H.R. 5719); Small business / national pooling of insurance health reform (S. 2795; H.R. 6210; H.R. 6582)
Client expense: $250,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Treasury, Dept of
2008 · fourth_quarter · Pharmacy
Advocate for cost containment policies, including generic access and the removal of barriers to greater competition in the pharmaceutical marketplace (including but not limited to H.R. 1038, S. 623, H.R. 5629, H.R. 1956, S. 1505, S. 1695). Food and Drug Administration Amendents Act of 2007 (H.R. 3580) Counterfeit Drugs/Import safety/Pedigree Electronic prescribing (including H.R. 6331, S. 2408, and H.R. 4296) Prescription drug importation/re-importation Average Manufacturers Price/AMP
Client expense: Not reported · Firm income: $40,000
Government targets: Congressional Budget Office (CBO), HOUSE OF REPRESENTATIVES, SENATE
2008 · fourth_quarter · Health Issues
Advocate for cost containment policies, including generic access and the removal of barriers to greater competition in the pharmaceutical marketplace (including but not limited to H.R. 1038, S. 623, H.R. 5629, H.R. 1956, S. 1505, S. 1695). Food and Drug Administration Amendents Act of 2007 (H.R. 3580) Counterfeit Drugs/Import safety/Pedigree Electronic prescribing (including H.R. 6331, S. 2408, and H.R. 4296) Prescription drug importation/re-importation Average Manufacturers Price/AMP
Client expense: Not reported · Firm income: $40,000
Government targets: Congressional Budget Office (CBO), HOUSE OF REPRESENTATIVES, SENATE
2008 · fourth_quarter · Pharmacy
-Advocated for cost containment policies including generic access, e-prescribing, and comparative effectiveness (including H.R. 1038 and S. 623) and policies that promote competition in the pharmaceutical marketplace (including but not limited to HR 5629, HR 1956, S 1505, and S. 1695).
Client expense: Not reported · Firm income: $30,000
Government targets: Congressional Budget Office (CBO), HOUSE OF REPRESENTATIVES, SENATE